Shuttle Pharmaceuticals Granted U.S. Patent #11654157: Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
Portfolio Pulse from Charles Gross
Shuttle Pharmaceuticals has been granted U.S. Patent #11654157 for methods and formulations in cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation. The patent covers treatment of cancer and neoplastic diseases in conjunction with radiation therapy.
May 23, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Shuttle Pharmaceuticals has been granted a U.S. patent for its cancer therapy methods and formulations, which could potentially lead to new treatment options and revenue streams.
The granting of the U.S. patent to Shuttle Pharmaceuticals for its cancer therapy methods and formulations is a significant milestone for the company. This could potentially lead to the development of new treatment options for cancer patients and open up new revenue streams for the company. As a result, this news is likely to have a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100